Build my stack
Home · Guides · NAD+ Injections

NAD+ Injection Benefits and Side Effects: What the Evidence Shows

Ready to buy? the vendor scorecard ranks every seller we review on lab tests, shipping and price, with reader codes.

The short answer

An NAD+ injection delivers nicotinamide adenine dinucleotide, a coenzyme found in every cell and a dinucleotide rather than a peptide, by needle instead of by mouth; a 2021 review reports that oral NAD+ does not effectively raise NAD+ in plasma or tissues. Human data on infused NAD+ is small: the one peer-reviewed study we found gave 8 healthy men 750 mg over 6 hours, measured plasma NAD+ about 398% above baseline at the end and reported no adverse events, while a 2024 preprint of 500 mg infusions reported more frequent and more severe infusion reactions with NAD+ than with nicotinamide riboside. Neither study tested whether NAD+ improves energy, ageing or any health outcome, we found no published results from a trial of subcutaneous NAD+, and the side effects most often listed, in a compounding pharmacy's overview and not in trials, are fatigue, nausea, headache, flushing with rapid injection and injection-site redness or burning. That pharmacy's page says NAD+ injection is not an FDA-approved drug, and FDA's 2019 proposed rule would not add NAD to the list of bulk substances pharmacies may compound from; FDA's compounding page, current as of 14 May 2026, shows no final rule.

This page covers what the published human studies on NAD+ infusions measured, what is reported about side effects, how the routes differ, what a vial costs on the research market, and where FDA stands. For milligram ranges and syringe arithmetic, the NAD+ injection dosage chart is the page that does that job.

Everything below is research use information. It is not medical advice, it is not a recommendation to start or stop anything, and none of it substitutes for supervision by a qualified clinician who can see your bloodwork and your history.

What an NAD+ Injection Actually Is

Nicotinamide adenine dinucleotide is a coenzyme, present in every cell, and it is not a peptide despite where it is sold. It has no amino acid chain: it is a dinucleotide, two nucleotides joined together, which makes it a different class of molecule from BPC-157 or sermorelin. Research chemical vendors list it alongside peptides, and nine vendors in the Bureau's Vendor Watch feed do.

A 2021 review in Aging and Disease describes NAD+ as an essential cofactor for redox reactions and energy metabolism, and names sirtuins, PARPs and CD38 among the enzymes that consume it. The same review says the body's NAD+ content decreases with age. Whether topping the pool back up improves anything meaningful in humans is the open question, and the human trials below do not answer it.

Why the Injectable Route Exists

The 2021 review reports that oral NAD+ cannot effectively increase NAD+ in plasma or in tissues, and gives two reasons: effects in the intestine that lower bioavailability, and the molecule's high polarity, which limits passive transport across membranes. Oral supplements use smaller precursors instead, nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), and cells can use NR to make NAD+.

Injecting sidesteps the gut, but that does not make the question simple. The 2019 infusion paper says enzymes in human serum can degrade NAD+ to AMP and NMN, and that because NAD+ carries a negative charge it cannot cross cell membranes passively, so uptake of the intact molecule would need active transport; it cites cell studies in which exogenous NAD+ raised intracellular NAD+ and says the mechanisms are not yet fully characterised. The 2021 review says increasing evidence indicates NAD+ cannot enter cells directly and must first be converted into smaller, less charged molecules, while also noting that a NAD+ transporter may recently have been identified. So how an injected dose reaches the cells that matter is still argued over, and neither human study below measured NAD+ in muscle, liver or any other solid tissue.

Subcutaneous Versus Intravenous

The published human work is intravenous. The 2019 study ran 750 mg of NAD+ in saline over 6 hours, which its authors call a typical clinical dosing regimen, and the 2024 preprint gave 500 mg in 500 mL of saline and recorded how long people could comfortably tolerate the infusion. In that preprint the mean tolerable infusion time for nicotinamide riboside was 75% shorter than for NAD+, which suggests infusion speed matters for how NAD+ is tolerated.

Subcutaneous and intramuscular injection are the routes discussed for use outside a clinic, and the amounts discussed are smaller. We found no published results from a trial of either route for NAD+. A registered trial, NCT06919328, is testing 100 mg of NAD+ in 2 mL of bacteriostatic water by subcutaneous, intramuscular and IV push injection against placebo, with injection pain and discomfort as its primary outcomes; its registry record, last updated 9 April 2025, posts no results. Until data exist, a clinic's IV amount and a home subcutaneous amount are different exposures, and we found no published comparison of them. The dosage chart lists the subcutaneous ranges as people report them, not as a tested protocol.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes

Reported Side Effects: Infusion Reactions, Stinging and the Flush

The controlled data first. In the 2019 study, 8 healthy men given 750 mg of NAD+ over 6 hours and 3 given saline had no adverse events during the infusion. Some liver blood tests fell and bilirubin rose slightly, and the authors said none of the changes were clinically significant. The control group was 3 people, and the authors note that a low sample number may reduce discrimination sensitivity. In the 2024 preprint, which has not been peer reviewed and compared NAD+ with a nicotinamide riboside product, the NAD+ arm had more frequent and more severe infusion reactions than the NR arm, and white blood cell and neutrophil counts rose in the NAD+ arm, which the authors read as a possible inflammatory response. No attributable adverse events were reported through 14 days of follow-up in any group.

Outside the trials, the descriptions come from pharmacies, clinics and users. A compounding pharmacy's NAD+ injection overview (Empower Pharmacy, opened 31 October 2026, no date shown on the page) lists fatigue, nausea, headache and lightheadedness as common reactions, warmth, flushing or dizziness especially with rapid injection, injection-site redness, tenderness or brief burning, and headache, chest tightness or dizziness during an infusion that it says is often relieved by pausing or slowing the infusion rate. The same page says robust evidence in humans remains limited. A 2021 review also states that direct administration of high doses of NAD+ can cause insomnia, fatigue, anxiety and other adverse reactions, citing an earlier report. These are descriptions, not measured trial findings. The rate-related flush that users talk about matches the pharmacy's wording about rapid injection, and the preprint's finding that NAD+ needed a longer tolerable infusion time than nicotinamide riboside points the same way.

Local stinging is a separate and also anecdotal complaint. Reconstituted NAD+ is often described as burning more than most research compounds, and the registered trial above is measuring injection pain directly, so better data may come. The injection technique guide covers site rotation and handling.

Reconstitution, Storage and Handling

NAD+ vials are usually described as reconstituted with bacteriostatic water, as with other vials in the category. The reconstitution guide covers the mechanics, the bacteriostatic water page explains why the preservative matters for a multi use vial, and the storage and stability guide covers temperature.

Stability is where NAD+ differs from many compounds on this site. In its 2019 proposed rule FDA wrote that NAD "degrades substantially when exposed to light, moisture, alkaline pH, or standard room temperatures" and would not be stable under ordinary storage conditions without multiple compensatory measures. That is the regulator's description of the bulk substance, not a storage protocol for any particular vial, so follow the written storage instructions that come with the one you hold.

Units on your syringe for NAD+

Enter the vial strength, the bacteriostatic water you added and your dose, and get the exact mark on the syringe. Free, no signup, and the result comes with a link you can share or save.

Open the NAD+ calculator peptulator.com, the Bureau's independent tool

How Often and How Much: What Is Actually Known

Both human studies gave a single infusion, so no trial we found has tested a repeat-dose schedule, a loading phase or a maintenance phase. Schedules quoted by clinics and forums are convention that circulated and was repeated, not trial design, and the Bureau reports them only as reported. The dosage chart sets out the subcutaneous ranges people report and how to convert milligrams into syringe units. For how NAD+ is discussed next to mitochondrial compounds, see the longevity peptides overview, MOTS-c and SS-31.

Benefits: What the Human Research Supports

For infused NAD+, the evidence is one peer-reviewed pharmacokinetic study and one preprint. The peer-reviewed study (Grant and colleagues, Frontiers in Aging Neuroscience, 2019) enrolled 11 healthy men aged 30 to 55 and found that plasma NAD+ and its metabolites did not change until after the first 2 hours of a 750 mg infusion; plasma NAD+ then reached about 398% above baseline at the 6 hour mark and was still raised at 8 hours. Its authors state that the metabolic fate and pharmacokinetics of IV NAD+ had not been reported in humans before. The preprint (Hawkins and colleagues, medRxiv, June 2024) analysed 37 people in a four-arm first part (IV NAD+, IV nicotinamide riboside, oral nicotinamide riboside or IV saline, 500 mg of each active product) and 16 in a second part comparing the two IV products. It reported that nicotinamide riboside IV gave a higher blood NAD+ reading than NAD+ IV at 3 hours, with fewer infusion reactions. It is not peer reviewed, and its registry title names a ChromaDex nicotinamide riboside product (Niagen), so NAD+ was the comparator rather than the product under test.

Most controlled work has used oral precursors. A 2023 review in Science Advances assessed the 25 published human nicotinamide riboside studies and reported that oral NR has been shown multiple times to raise NAD+ in whole blood but has displayed few clinically relevant effects, adding that the literature tends to exaggerate the importance and robustness of reported effects. That is the nearest evidence on whether raising blood NAD+ does anything people care about, and it is for an oral precursor, not for an injection.

So the position is this: a plausible biochemical rationale, a reported decline in NAD+ with age, evidence from one small infusion study that plasma levels can be raised, and no study we found showing that injecting NAD+ improves any outcome people take it for. That is an absence of evidence, not evidence of no effect, and a route more invasive than a capsule deserves a clear view of how large the absence is.

Safety Questions That Are Still Open

Both human studies enrolled healthy adults, the 2019 study only men aged 30 to 55, and followed them for hours to 14 days after one infusion. They say little about repeated use over months or years, pregnancy, breastfeeding, or people with medical conditions or on medication. FDA's 2019 review went further: it found nonclinical data in the literature inadequate to characterise the toxicity profile of NAD, particularly for use in a chronic disease, and did not find sufficient clinical data to evaluate whether NAD is safe in compounded drug products. Those are gaps in the data, not findings of harm, and they are the reason the Bureau treats NAD+ as research information only.

The risk that has nothing to do with the molecule applies here as much as anywhere: a vial label does not by itself establish identity, purity or sterility, and how to spot a fake vendor is a more useful safety read than any dose table. The general safety page makes the same case at the category level, and the research peptide legal status guide covers the wider regulatory picture.

See also: NAD+ nasal spray: what the research shows.

See also: glutathione injections, the other popular wellness shot, and what the trials found.

Frequently Asked Questions

What is an NAD+ injection?

An NAD+ injection delivers nicotinamide adenine dinucleotide, a coenzyme found in every cell, under the skin, into muscle or into a vein instead of by mouth. It is sold alongside peptides, but it is a dinucleotide rather than an amino acid chain, so it is not a peptide. A 2021 review reports that oral NAD+ does not effectively raise NAD+ in plasma or tissues, and oral supplements use precursors such as nicotinamide riboside and NMN instead.

Do NAD+ injections work?

No study we found shows a health benefit from injected NAD+. The best human data is a 2019 study in which 8 healthy men received 750 mg of NAD+ over 6 hours and 3 received saline: plasma NAD+ was about 398% above baseline at the end of the infusion, which shows blood levels can be raised but did not test energy, ageing or any health outcome. A 2023 review of 25 published human studies of oral nicotinamide riboside found it raised blood NAD+ but displayed few clinically relevant effects.

What are the side effects of NAD+ injections?

In the 2019 infusion study, 750 mg of NAD+ over 6 hours caused no adverse events in the 8 men who received it, and the authors judged small changes in liver blood tests not clinically significant. A 2024 preprint, which has not been peer reviewed, reported that a 500 mg NAD+ infusion caused more frequent and more severe infusion reactions than nicotinamide riboside, with a rise in white blood cell counts and neutrophils. A 2021 review states that direct administration of high doses of NAD+ can cause insomnia, fatigue and anxiety. A compounding pharmacy's overview lists fatigue, nausea, headache, lightheadedness, flushing with rapid injection and injection-site redness or burning, but those are descriptions rather than trial results. Neither study followed people for more than 14 days after a single infusion, so neither says anything about long-term use.

What is the dosage for NAD+ injections?

We found no trial that establishes a dose for injected NAD+. The human infusion studies we found used 750 mg over 6 hours (2019) and 500 mg in 500 mL of saline (2024 preprint), and a registered trial is testing 100 mg by subcutaneous, intramuscular and IV push injection. Amounts quoted for home subcutaneous use come from forums and vendors rather than trials, so the Bureau reports them only as reported, and its dosage chart lists them with the syringe arithmetic.

What is the difference between NAD+ injection and NAD+ IV?

The published human data is intravenous. The 2019 study ran 750 mg over 6 hours, and the 2024 preprint gave 500 mg in 500 mL of saline and recorded how long people could comfortably tolerate the infusion, which was longer for NAD+ than for nicotinamide riboside. We found no published results from a trial of subcutaneous or intramuscular NAD+. A registered trial, NCT06919328, is testing 100 mg of NAD+ in 2 mL of bacteriostatic water by subcutaneous, intramuscular and IV push injection against placebo, and its registry record, last updated 9 April 2025, posts no results.

How often are NAD+ injections given?

No trial we found has tested a repeat-dose schedule: the 2019 study and the 2024 preprint each gave one infusion. Schedules quoted by clinics and forums are convention rather than trial results, so the Bureau reports them only as reported, never as a recommendation.

How much do NAD+ injections cost?

For research-use vials, the Bureau's Vendor Watch feed lists NAD+ at nine vendors. Single-vial list prices read on 31 October 2026, before any code, were USD 44 to 125 for 500 mg and USD 60 to 230 for 1,000 mg, with seven vendors listing each size in stock. That is the price of a whole vial, not of a dose. Clinic and telehealth session prices vary by provider and we did not check any provider's live price page for this update, so we give no figure for them.

Are NAD+ injections FDA approved?

One compounding pharmacy's own NAD+ page, opened on 31 October 2026, states that NAD+ injection is not an FDA-approved drug and that safety and efficacy for the formulation have not been evaluated by FDA. We also searched FDA's Drugs@FDA data through openFDA on 31 October 2026 for NAD, NADH and nicotinamide adenine dinucleotide as an active ingredient and got no match. For compounding, FDA says 503A pharmacies may only use bulk substances that meet a USP or NF monograph, are components of FDA-approved drugs, or appear on FDA's 503A bulks list. In a 2019 proposed rule FDA said it would not add NAD to that list, citing too little safety and effectiveness data for the use it evaluated (fatigue in multiple sclerosis) and poor stability, and FDA's page, current as of 14 May 2026, still says a final regulation will follow.

Sources

  1. She J, Sheng R, Qin ZH. Pharmacology and Potential Implications of Nicotinamide Adenine Dinucleotide Precursors. Aging and Disease 2021;12(8):1879-1897: PMC8612620. Checked 31 October 2026.
  2. Grant R, Berg J, Mestayer R, et al. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Frontiers in Aging Neuroscience 2019;11:257: PMC6751327. Checked 31 October 2026.
  3. Hawkins J, et al. Randomized, placebo-controlled, pilot clinical study evaluating acute Niagen+ IV and NAD+ IV in healthy adults. medRxiv preprint, first posted 10 June 2024, not peer reviewed (abstract read through Europe PMC): doi 10.1101/2024.06.06.24308565. Checked 31 October 2026.
  4. ClinicalTrials.gov record NCT06382688, IV Administration of ChromaDex's Niagen as Compared to NAD+ (500 mg arms; last updated 24 April 2024; no results posted): NCT06382688. Checked 31 October 2026.
  5. ClinicalTrials.gov record NCT06919328, Absorption and Tolerability of Injectable Administration of Niagen+ as Compared to NAD+ (100 mg subcutaneous, intramuscular and IV push arms; last updated 9 April 2025; no results posted): NCT06919328. Checked 31 October 2026.
  6. Damgaard MV, Treebak JT. What is really known about the effects of nicotinamide riboside supplementation in humans. Science Advances 2023;9(29):eadi4862: PMC10361580. Checked 31 October 2026.
  7. FDA, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, content current as of 14 May 2026: fda.gov. Checked 31 October 2026.
  8. Federal Register, Vol. 84, No. 172, 5 September 2019, Amendments to the List of Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503A (proposed rule, Docket FDA-2018-N-4845), entry on NAD: govinfo.gov PDF. Checked 31 October 2026.
  9. openFDA Drugs@FDA API, active-ingredient searches for NAD, NADH and nicotinamide adenine dinucleotide, run 31 October 2026 (no matches): open.fda.gov.
  10. Empower Pharmacy, NAD+ Injection overview (a compounding pharmacy's own page; no date shown on the page): empowerpharmacy.com. Opened 31 October 2026. Cited only for the side effects it lists and its statements on evidence and FDA status, not for any dose.
  11. Peptide Bureau Vendor Watch price feed, single-vial NAD+ list prices fetched 31 October 2026 at 07:30 UTC, before any code.

Figures from the sources above, checked 31 October 2026. Preprints are not peer reviewed and registry records can change. Research use information only, not medical advice.

PB
The Peptide Bureau editorial desk. Peptide Bureau is a small independent research team covering peptide dosing, safety and vendors. We are not clinicians; nothing here is medical advice. How the Bureau works.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes